Steven Cohen’s Accelerate Diagnostics AXDX Stock Holding History

Steven Cohen’s Portfolio AXDX Stock Details AXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,564	Closed	-$1.17M	–	1333
2019 Q1	$1.17M	Buy	+5,564	New	+$1.04M	0.01%	788

Other funds holding AXDX

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Steven Cohen's AXDX Position: Q2 2019 in Review

Steven Cohen sold out of Accelerate Diagnostics (AXDX) in Q2 2019, closing a stake of 5,564 shares — an estimated $1.17M sold.

Steven Cohen first reported a position in AXDX in Q1 2019 and held it in 1 quarter. The position peaked at $1.17M in Q1 2019. 117 funds tracked by Wall St. Rank hold AXDX as of Q2 2019.

Steven Cohen reported no remaining Accelerate Diagnostics position as of Q2 2019 after selling out during the quarter.
Steven Cohen sold 5,564 Accelerate Diagnostics shares in Q2 2019, an estimated $1.17M.
Steven Cohen first reported a position in Accelerate Diagnostics in Q1 2019 and held it in 1 quarter.
Steven Cohen's Accelerate Diagnostics position peaked at $1.17M in Q1 2019.
117 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q2 2019.

Based on Point72 Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.